Xbiome
PrivateLast Round
Series B
Extension
Dec 22, 2021
Total Funding Raised
$141.5M
Company Overview
Xbiome operates in Healthcare & Life Sciences and is based in Shenzhen. Its latest recorded funding round was a Series B Extension round in December 2021.
Xbiome is a biotechnology company that develops an AI-driven drug discovery platform and microbial pharmaceuticals for treating intestinal disorders and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xbiome Comparables
Compare Xbiome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shenzhen 01 Life Technology Co., Ltd. | 79% | |
| Evogene | 77% | |
| Enterome | 76% |
For institutional investors. Book with your work email.
Xbiome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 22, 2021 | ||||
| Series B Extension | Dec 1, 2020 | ||||
| Series B | Nov 4, 2019 | ||||
| Series A Extension | Jan 3, 2019 | ||||
| Series A | Aug 3, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xbiome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tsinghua Shenzhen International Graduate School | Series A Extension |
| ZhenFund | Series A |
| Tiantu Capital | Series B Extension |
| HIKE Capital | Series B Extension |
| Legend Capital | Series B Extension, Series B |
| 5Y Capital | Series B, Series B Extension, Series A |
| Primavera Venture Partners | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 11, 2025
Monthly visitors grew 249% MoM, from 35 to 122.
- Nov 4, 2019
$14M round led by Legend Capital.
For institutional investors. Book with your work email.
Xbiome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xbiome's valuation, stock price, and market status.
Is Xbiome a public or private company?
Xbiome is a private company.
What is the current stock price of Xbiome?
Xbiome is a private company, so its shares have no public market price. Caplight tracks Xbiome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xbiome worth (valuation)?
Valuation information for Xbiome is not publicly available.
Can I buy Xbiome stock?
Xbiome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xbiome's last funding round?
Xbiome's most recent funding round was Series B Extension on December 22, 2021.
Who are the main investors in Xbiome?
Key investors in Xbiome include Tsinghua Shenzhen International Graduate School, Legend Capital, Primavera Venture Partners, Gaorong Capital.
Will Xbiome IPO soon?
No public IPO plans have been announced for Xbiome.
How can I track Xbiome secondary market activity?
Caplight tracks bids, offers, and trades in Xbiome's shares on secondary markets.